换一批Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
第一作者：
Filipe Correia,Martins
第一单位：
Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, England.;Experimental Medicine Initiative, University of Cambridge, Cambridge, England.;Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, England.
作者：
Filipe Correia,Martins [1]
;
Dominique-Laurent,Couturier [2]
;
Anna,Paterson [3]
;
Anthony N,Karnezis [4]
;
Christine,Chow [5]
;
Tayyebeh M,Nazeran [6]
;
Adekunle,Odunsi [7]
;
Aleksandra,Gentry-Maharaj [8]
;
Aleksandra,Vrvilo [9]
;
Alexander,Hein [10]
;
Aline,Talhouk [11]
;
Ana,Osorio [12]
;
Andreas D,Hartkopf [13]
;
Angela,Brooks-Wilson [14]
;
Anna,DeFazio [15]
;
Anna,Fischer [16]
;
Arndt,Hartmann [17]
;
Brenda Y,Hernandez [18]
;
Bryan M,McCauley [19]
;
Chloe,Karpinskyj [8]
;
Christiani B,de Sousa [20]
;
Claus,Høgdall [21]
;
Daniel G,Tiezzi [20]
;
Esther,Herpel [22]
;
Florin Andrei,Taran [13]
;
Francesmary,Modugno [23]
;
Gary,Keeney [19]
;
Gregg,Nelson [24]
;
Helen,Steed [25]
;
Honglin,Song [26]
;
Hugh,Luk [27]
;
Javier,Benitez [12]
;
Jennifer,Alsop [26]
;
Jennifer M,Koziak [28]
;
Jenny,Lester [29]
;
Joseph H,Rothstein [30]
;
Jurandyr M,de Andrade [20]
;
Lene,Lundvall [21]
;
Luis,Paz-Ares [31]
;
Luis,Robles-Díaz [32]
;
Lynne R,Wilkens [27]
;
Maria J,Garcia [12]
;
Maria P,Intermaggio [33]
;
Marie-Lyne,Alcaraz [26]
;
Mary A,Brett [34]
;
Matthias W,Beckmann [10]
;
Mercedes,Jimenez-Linan [3]
;
Michael,Anglesio [35]
;
Michael E,Carney [36]
;
Michael,Schneider [10]
;
Nadia,Traficante [37]
;
Nadja,Pejovic [38]
;
Naveena,Singh [39]
;
Nhu,Le [40]
;
Peter,Sinn [41]
;
Prafull,Ghatage [24]
;
Ramona,Erber [17]
;
Robert,Edwards [23]
;
Robert,Vierkant [19]
;
Roberta B,Ness [42]
;
Samuel,Leung [5]
;
Sandra,Orsulic [29]
;
Sara Y,Brucker [13]
;
Scott H,Kaufmann [19]
;
Sian,Fereday [37]
;
Simon,Gayther [43]
;
Stacey J,Winham [19]
;
Stefan,Kommoss [13]
;
Tanja,Pejovic [9]
;
Teri A,Longacre [44]
;
Valerie,McGuire [45]
;
Valerie,Rhenius [26]
;
Weiva,Sieh [30]
;
Yurii B,Shvetsov [46]
;
Alice S,Whittemore [47]
;
Annette,Staebler [16]
;
Beth Y,Karlan [29]
;
Cristina,Rodriguez-Antona [48]
;
David D,Bowtell [49]
;
Ellen L,Goode [19]
;
Estrid,Høgdall [50]
;
Francisco J,Candido Dos Reis [20]
;
Jacek,Gronwald [51]
;
Jenny,Chang-Claude [52]
;
Kirsten B,Moysich [7]
;
Linda E,Kelemen [53]
;
Linda S,Cook [54]
;
Marc T,Goodman [55]
;
Peter A,Fasching [56]
;
Robin,Crawford [57]
;
Suha,Deen [58]
;
Usha,Menon [8]
;
David G,Huntsman [59]
;
Martin,Köbel [34]
;
Susan J,Ramus [60]
;
Paul D P,Pharoah [61]
;
James D,Brenton [62]
作者单位：
Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, England.;Experimental Medicine Initiative, University of Cambridge, Cambridge, England.;Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, England.
[1]
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, England.
[2]
Department of Histopathology, Addenbrookes Hospital, Cambridge, England.
[3]
Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA, USA.
[4]
OVCARE, Vancouver Coastal Health Research Centre, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada.
[5]
Department of Molecular Oncology and Department of Pathology and Laboratory Medicine, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada.
[6]
Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
[7]
MRC CTU, Institute of Clinical Trials and Methodology, University College London, London, England.
[8]
Department of Ob/Gyn, Oregon Health & Science University, Portland, OR, USA.
[9]
Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
[10]
Department of Molecular Oncology and Department of Pathology and Laboratory Medicine, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada.;Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.;Department of Molecular Oncology, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada.
[11]
Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.;Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
[12]
Department of Women's Health, Tübingen University Hospital, Tübingen, Germany.
[13]
Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
[14]
Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia.;Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia.
[15]
Institute of Pathology, Tübingen University Hospital, Tübingen, Germany.
[16]
Institute of Pathology, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
[17]
Cancer Center, University of Hawaii, Honolulu, HI, USA.
[18]
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
[19]
Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
[20]
Department of Gynaecology, Rigshospitalet, University Hospital Copenhagen, Blegdamsvej 9, 2100, København, Denmark.
[21]
NCT Tissue Bank, National Center for Tumour Diseases, Heidelberg, Germany.;Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
[22]
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
[23]
Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
[24]
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Royal Alexandra Hospital, Edmonton, AB, Canada.
[25]
Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, England.
[26]
Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
[27]
Alberta Health Services-Cancer Care, Calgary, AB, Canada.
[28]
Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
[29]
Department of Population Health Science and Policy and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
[30]
Spanish National Cancer Research Center, CNIO Lung Cancer Clinical Research Unit, New York, NY, USA.
[31]
Familial Cancer Unit and Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
[32]
School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.
[33]
Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
[34]
OVCARE, Vancouver Coastal Health Research Centre, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada.;Department of Molecular Oncology and Department of Pathology and Laboratory Medicine, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada.;Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
[35]
John A. Burns School of Medicine, Department of Obstetrics and Gynecology, University of Hawaii, Honolulu, HI, USA.
[36]
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.;Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
[37]
School of Medicine, St. Louis University, St. Louis, MO, 63103, USA.
[38]
Department of Cellular Pathology, Barts Health National Health Service Trust, London, England.
[39]
Cancer Control Research, British Columbia Cancer Agency, Vancouver, BC, Canada.
[40]
Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
[41]
University of Texas School of Public Health, Houston, TX, USA.
[42]
Cedars-Sinai Center for Bioinformatics and Functional Genomics, Los Angeles, CA, USA.
[43]
Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
[44]
Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA.
[45]
Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.;Department of Pathology, University of Melbourne, Melbourne, VIC, Australia.
[46]
Department of Health Research and Policy and Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
[47]
Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.;Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid, Madrid, Spain.
[48]
Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.;Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Parkville, VIC, Australia.;The Garvan Institute, Sydney, NSW, Australia.
[49]
Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.;Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.;Cancer Genomics Program, Research Department, Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
[50]
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
[51]
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
[52]
Department of Public Health Sciences, Medical University of South Carolina and Hollings Cancer Center, Charleston, SC, USA.
[53]
Division of Epidemiology, Biostatistics and Preventative Medicine, University of New Mexico, Albuquerque, NM, USA.
[54]
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
[55]
Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.;David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, 90095, USA.
[56]
Division of Oncology, Addenbrookes Hospital, Cambridge, England.
[57]
Department of Histopathology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, England.
[58]
OVCARE, Vancouver Coastal Health Research Centre, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada.;Department of Molecular Oncology and Department of Pathology and Laboratory Medicine, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada.;Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.;Department of Molecular Oncology, BC Cancer Research Centre, BC Cancer, Vancouver, BC, Canada.
[59]
School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.;The Garvan Institute, Sydney, NSW, Australia.
[60]
Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Cambridge, England. pp10001@medschl.cam.ac.uk.;Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Worts Causeway, Cambridge, England. pp10001@medschl.cam.ac.uk.;Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, England. pp10001@medschl.cam.ac.uk.
[61]
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, England. james.brenton@cruk.cam.ac.uk.;Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, England. james.brenton@cruk.cam.ac.uk.;Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, England. james.brenton@cruk.cam.ac.uk.
[62]
医学主题词
腺癌, 透明细胞(Adenocarcinoma, Clear Cell);年龄因素(Age Factors);队列研究(Cohort Studies);减量调节(Down-Regulation);女(雌)性(Female);基因敲除技术(Gene Knockout Techniques);人类(Humans);中年人(Middle Aged);肿瘤分期(Neoplasm Staging);卵巢肿瘤(Ovarian Neoplasms);PTEN磷酸水解酶(PTEN Phosphohydrolase);前瞻性研究(Prospective Studies);受体, 雄激素(Receptors, Androgen);受体, 雌激素(Receptors, Estrogen);受体, 孕酮(Receptors, Progesterone);组织阵列分析(Tissue Array Analysis);肿瘤抑制蛋白质类(Tumor Suppressor Proteins)
DOI
10.1038/s41416-020-0900-0
PMID
32555365
发布时间
2025-09-04
- 浏览2
British journal of cancer
British journal of cancer
793-802页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
